Travere Therapeutics (TVTX) Change in Receivables (2014 - 2026)

Travere Therapeutics' Change in Receivables history runs 13 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• Quarterly Change in Receivables changed 0.29% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.8 million (up 138.83% YoY) and the FY2025 annual result came in at $27.8 million, up 363.62% from the prior year.
• Change in Receivables was $7.2 million for Q1 2026 at Travere Therapeutics, up from -$27.8 million in the prior quarter.
• Across five years, Change in Receivables topped out at $44.2 million in Q3 2025 and bottomed at -$27.8 million in Q4 2025.
• A 5-year average of $3.1 million and a median of $2.0 million in 2024 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 5940.36% in 2025, while the deepest fall reached 1502.17% in 2025.
• Travere Therapeutics' Change in Receivables stood at $6.0 million in 2022, then surged by 32.73% to $8.0 million in 2023, then plunged by 75.1% to $2.0 million in 2024, then sank by 1502.17% to -$27.8 million in 2025, then soared by 125.97% to $7.2 million in 2026.
• Business Quant data shows TVTX's Change in Receivables at $7.2 million in Q1 2026, -$27.8 million in Q4 2025, and $44.2 million in Q3 2025.